Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Theravance Biopharma, Inc. (TBPH)  
$8.77 0.11 (1.24%) as of 4:30 Fri 6/7


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 63,980,000
Market Cap: 561.10(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $8.22 - $11.59
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 18.6
Insider 6 Months    : 18.6
Insider 3/6 Months : 37.7
Guru Rank Number :  245
Guru Rank Value     : 4.8
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1,499,124 1,499,124 1,499,124 1,499,124
Total Buy Value $13,117,335 $13,117,335 $13,117,335 $13,117,335
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 1 1
Total Shares Sold 0 1,254 18,851 171,008
Total Sell Value $0 $10,922 $185,406 $1,825,540
Total People Sold 0 1 2 4
Total Sell Transactions 0 1 9 20
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 535
  Page 4 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sawaf Aziz SVP & Chief Financial Officer   •       –      –    2023-01-01 3 IO $0.00 $0 D/D 0 204,500 3%     
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2022-12-14 4 S $11.19 $559,500 D/D (50,000) 1,350,797 1%     
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2022-12-13 4 GD $0.00 $0 D/D 9,000 1,400,797     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2022-12-01 4 S $10.73 $22,361 D/D (2,084) 313,520 -10%     
   Oconnor Donal   –       •      –    2022-11-22 4 D $10.50 $105,000 D/D (10,000) 43,886     -
   Hindman Andrew A. SVP, CHIEF FINANCIAL OFFICER   •       –      –    2022-11-20 4 D $10.85 $271,868 D/D (25,057) 384,714     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2022-11-20 4 D $10.85 $252,458 D/D (23,268) 296,309     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2022-11-20 4 D $10.85 $171,473 D/D (15,804) 1,409,797     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2022-11-20 4 D $10.85 $296,748 D/D (27,350) 315,604     -
   Hindman Andrew A. SVP, CHIEF FINANCIAL OFFICER   •       –      –    2022-11-18 4 S $11.02 $716,242 D/D (65,000) 409,771 -4%     
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2022-11-16 4 D $11.20 $31,360 D/D (2,800) 342,954     -
   Samaha Eli 10% Owner   –       –       •   2022-09-20 3 IO $0.00 $0 I/I 0 7,012,226 4%     
   Wam Gp Llc 10% Owner   –       –       •   2022-09-19 3 IO $0.00 $0 I/I 0 7,457,060 6%     
   Glaxosmithkline Plc Former 10% Owner   –       –      –    2022-09-16 4 D $9.75 $94,036,868 I/I (9,644,807) 0     -
   Hindman Andrew A. SVP, CHIEF FINANCIAL OFFICER   •       –      –    2022-08-19 4 D $9.34 $239,814 D/D (25,676) 473,507     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2022-08-19 4 D $9.34 $147,609 D/D (15,804) 1,424,784     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2022-08-19 4 D $9.34 $97,257 D/D (10,413) 319,577     -
   Graham Richard A SVP, DEVELOPMENT   •       –      –    2022-08-19 4 D $9.34 $177,376 D/D (18,991) 345,754     -
   Graham Richard A SVP, DEVELOPMENT   •       –      –    2022-08-16 4 S $9.71 $47,640 D/D (4,906) 364,745 -14%     
   Graham Richard A SVP, DEVELOPMENT   •       –      –    2022-08-09 4 S $8.79 $132,606 D/D (15,086) 369,651 -20%     
   Hindman Andrew A. SVP, CHIEF FINANCIAL OFFICER   •       –      –    2022-07-25 4 A $0.00 $0 D/D 20,000 499,183     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2022-05-23 4 AS $8.93 $9,653 D/D (1,081) 329,990 7%     
   Graham Richard A SVP, DEVELOPMENT   •       –      –    2022-05-20 4 D $8.74 $34,497 D/D (3,947) 384,737     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2022-05-20 4 D $8.74 $19,228 D/D (2,200) 331,071     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2022-05-20 4 D $8.74 $96,359 D/D (11,025) 1,440,588     -
  535 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us